Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
Dario Giugliano, Luca De Nicola, Maria Ida Maiorino, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
Jae‐Seung Yun, Seung‐Hyun Ko
Metabolism (2021) Vol. 123, pp. 154838-154838
Open Access | Times Cited: 181
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 149
Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
О. М. Драпкина, А. V. Kontsevaya, А. М. Калинина, et al.
CARDIOVASCULAR THERAPY AND PREVENTION (2024) Vol. 23, Iss. 3, pp. 3696-3696
Open Access | Times Cited: 15
Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class
Hideaki Kaneto, Atsushi Obata, Tomohiko Kimura, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 6, pp. 3062-3062
Open Access | Times Cited: 37
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 34
Nephroprotection by SGLT2 Inhibition: Back to the Future?
Luca De Nicola, Francis B. Gabbai, Carlo Garofalo, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 7, pp. 2243-2243
Open Access | Times Cited: 36
Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects
Pia Clara Pafundi, Carlo Garofalo, Raffaele Galiero, et al.
Diagnostics (2021) Vol. 11, Iss. 2, pp. 290-290
Open Access | Times Cited: 28
Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
Caiyun Zheng, Meimei Lin, Yan Chen, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 28
Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta‐analysis
Qi Tian, Keyu Guo, Jiayi Deng, et al.
Journal of Cellular and Molecular Medicine (2021) Vol. 26, Iss. 2, pp. 540-547
Open Access | Times Cited: 28
The residual cardiorenal risk in type 2 diabetes
Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 24
Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future
Ritwika Mallik, Tahseen A Chowdhury
Therapeutic Advances in Endocrinology and Metabolism (2022) Vol. 13
Open Access | Times Cited: 18
The role of comorbidities on mortality of COVID-19 in patients with diabetes
Amir Emami, Ali Akbari, Atefeh Basirat, et al.
Obesity Medicine (2021) Vol. 25, pp. 100352-100352
Open Access | Times Cited: 23
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
Christian Ott, Susanne Jung, Manuel Korn, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 23
SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study
Gordon Chun‐Kau Chan, Jack Kit‐Chung Ng, Kai Ming Chow, et al.
Diabetes Research and Clinical Practice (2022) Vol. 195, pp. 110200-110200
Closed Access | Times Cited: 14
Nephroprotection by SGLT2i in CKD Patients: May It Be Modulated by Low-Protein Plant-Based Diets?
Adamasco Cupisti, Domenico Giannese, Diego Moriconi, et al.
Frontiers in Medicine (2020) Vol. 7
Open Access | Times Cited: 18
From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors
Cheng‐Yang Hsieh, Sheng‐Feng Sung
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 351-351
Open Access | Times Cited: 10
Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial
Atsushi Tanaka, Michio Shimabukuro, Yosuke Okada, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 15
The risk trajectory of different cardiovascular morbidities associated with chronic kidney disease among patients with newly diagnosed diabetes mellitus: a propensity score-matched cohort analysis
Chia‐Ter Chao, Szu‐Ying Lee, Jui Wang, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 13
Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease
Demetria Hubbard, Lisandro D. Colantonio, Robert S. Rosenson, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 11
Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases
Limin Zhao, Huang Jian-an, Mei Qiu, et al.
Medicine (2021) Vol. 100, Iss. 39, pp. e27362-e27362
Open Access | Times Cited: 11
The Role of SGLT2 Inhibitors on Treatment of Heart Failure, Mode of Actions
Raid M. Al Abood, Dunia Al-Naemi
Family Medicine and Primary Care Open Access (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 1
Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations
Alper Sönmez, Hani Sabbour, Akram Echtay, et al.
Journal of Diabetes (2022) Vol. 14, Iss. 5, pp. 315-333
Open Access | Times Cited: 7
Increasing serum miR-409-3p predicts the major adverse cardiac adverse events in elderly patients after hip fracture surgery
Zhengtao Sun, Kai Cheng, Guochao Jin, et al.
BMC Musculoskeletal Disorders (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Метаболічні ефекти інгібіторів натрійзалежного котранспортера глюкози 2 типу
А. В. Кедик, О. О. Куцин
Clinical endocrinology and endocrine surgery (2022), Iss. 4, pp. 42-58
Open Access | Times Cited: 2
Metabolic effects of empagliflozine
Antonina Kedyk, Oleksandr Kutsyn
Diabetes Obesity Metabolic Syndrome (2022), Iss. 5, pp. 38-56
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top